ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
23 hedge funds and large institutions have $11.3M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
32% more capital invested
Capital invested by funds: $8.55M → $11.3M (+$2.73M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 22 → 23 (+1)
1.41% more ownership
Funds ownership: 26.1% → 27.51% (+1.4%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$373K |
| 2 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$291K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$281K |
| 4 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$118K |
| 5 |
Morgan Stanley
New York
|
+$56.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$297K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$108K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$80.2K |
| 4 |
LPL Financial
San Diego,
California
|
-$73.8K |
| 5 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
-$28.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FAAS
26
First Allied Advisory Services
San Diego,
California
| – | -$18K | -955 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$3K | -134 | Closed |
|
28
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1K | -40 | Closed |
|
CNCR Hedge Fund Activity: Q4 2019 in Review
23 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2019, worth a combined $11.3M — up 32% from $8.55M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNCR positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $373K. The largest seller was SeaCrest Wealth Management, exiting entirely with an estimated $297K sold.
- 23 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2019, up from 22 in Q3 2019.
- Funds reported $11.3M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2019, up 32% quarter-over-quarter.
- 6 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2019 and 5 closed out, a net change of +1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2019 was Goldman Sachs, an estimated $373K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2019 was SeaCrest Wealth Management, an estimated $297K sold.
Based on aggregated 13F filings for Q4 2019.